全文获取类型
收费全文 | 6245篇 |
免费 | 569篇 |
国内免费 | 133篇 |
专业分类
耳鼻咽喉 | 47篇 |
儿科学 | 109篇 |
妇产科学 | 296篇 |
基础医学 | 740篇 |
口腔科学 | 141篇 |
临床医学 | 738篇 |
内科学 | 1400篇 |
皮肤病学 | 86篇 |
神经病学 | 611篇 |
特种医学 | 352篇 |
外科学 | 701篇 |
综合类 | 141篇 |
一般理论 | 2篇 |
预防医学 | 362篇 |
眼科学 | 168篇 |
药学 | 415篇 |
中国医学 | 62篇 |
肿瘤学 | 576篇 |
出版年
2023年 | 31篇 |
2022年 | 14篇 |
2021年 | 125篇 |
2020年 | 84篇 |
2019年 | 183篇 |
2018年 | 205篇 |
2017年 | 167篇 |
2016年 | 188篇 |
2015年 | 237篇 |
2014年 | 274篇 |
2013年 | 340篇 |
2012年 | 438篇 |
2011年 | 471篇 |
2010年 | 309篇 |
2009年 | 291篇 |
2008年 | 333篇 |
2007年 | 358篇 |
2006年 | 368篇 |
2005年 | 279篇 |
2004年 | 264篇 |
2003年 | 237篇 |
2002年 | 204篇 |
2001年 | 160篇 |
2000年 | 152篇 |
1999年 | 123篇 |
1998年 | 70篇 |
1997年 | 56篇 |
1996年 | 49篇 |
1995年 | 40篇 |
1994年 | 48篇 |
1993年 | 39篇 |
1992年 | 82篇 |
1991年 | 82篇 |
1990年 | 68篇 |
1989年 | 71篇 |
1988年 | 46篇 |
1987年 | 41篇 |
1986年 | 52篇 |
1985年 | 36篇 |
1984年 | 30篇 |
1983年 | 34篇 |
1982年 | 24篇 |
1981年 | 22篇 |
1979年 | 20篇 |
1978年 | 21篇 |
1977年 | 18篇 |
1975年 | 14篇 |
1974年 | 30篇 |
1973年 | 21篇 |
1972年 | 18篇 |
排序方式: 共有6947条查询结果,搜索用时 17 毫秒
1.
ChiaChi Lin TsaiSheng Yang ChiaJui Yen Rebecca Cheng Junjun Liu Chiun Hsu 《The oncologist》2020,25(12)
Lessons Learned
- The combination of ramucirumab (8 mg/kg intravenous, day 1 every 2 weeks) and FOLFOX4 as first‐line treatment in patients with advanced hepatocellular carcinoma (HCC) was not sufficiently tolerated.
- Preliminary efficacy data suggest that the combination may provide clinical benefit to patients with HCC.
- Dose modification and patient selection should be considered for the future development of ramucirumab plus FOLFOX chemotherapy for advanced HCC.
2.
3.
Activity and Toxicity of Eleutherine palmifolia (L.) Merr. Extract on BALB/c Mice Colitis-Associated Colon Cancer Model 下载免费PDF全文
Roihatul MutiahRiza Ambar SariWahyi Yucha FirsyaradhaAnik ListiyanaYen Yen Ari IndrawijayaAbdul WafiArief SuryadinataRetno SusilowatiAna Rahmawati 《Asian Pacific journal of cancer prevention》2020,21(12):3579-3586
Objective: Eleutherine palmifolia (L.) Merr. extract (EPE) containing isoliquiritigenin and oxyresveratrol is believed to be an anticancer agent. This study evaluates colon histopathology, TNF-α, TGF-β, and hepatotoxicity on BALB/c mice colitis-associated colon cancer (CAC) model treated with EPE. Methods: In vivo study was performed on BALB/c mice CAC model induced by 10 mg/kgBW AOM on the first day followed by administration that each cycle consisted of 5% DSS in water for seven days and regular water for seven days. The indicators of the formation of CAC were observed by a fecal occult blood test (FOBT) and serum amyloid α (SAA) test. The treatment was conducted once a week started from the seventh week up to the twentieth week with six treatment groups: I was administrated by regular water only (negative control), II was administrated by AOM and DSS only (positive control), III was administrated by doxorubicin, IV-VI were treated by EPE (0.25 mg/kg BW, 0.50 mg/kg BW, and 1.00 mg/kg BW) respectively. The colon and liver’s histopathology was observed using hematoxylin-eosin (HE) staining, TNF-α with immunohistochemistry (IHC), and level measurement of TGF-β colon with ELISA reader. The data were used one-way ANOVA followed by post hoc as statistical analysis. Results: The administration of EPE increased the expression of TNF-α, the total of goblet cells of the colon, and decreased the level of TGF-β. Administration of EPE 0.50 mg/20g BW decreased a liver histopathological score but induced a histopathological alteration of the liver at a dose of 1.00 mg/20g BW. Conclusion: This study indicate that EPE could be recommended as a colon anticancer through increase the goblet cells, induce apoptosis through increase TNF-α, and decrease TGF-β. 相似文献
4.
5.
6.
Chun A. Changou Her-Shyong Shiah Li-Tzong Chen Servina Liu Frank Luh Shwu-Huey Liu Yung-Chi Cheng Yun Yen 《The oncologist》2021,26(3):e367-e373
Lessons Learned
- A PHY906 and capecitabine combination could be effective as a salvage therapy for patients with hepatocellular carcinoma (HCC) previously treated with multiple systemic therapies.
- This traditional Chinese medicine formulation can work with Western cancer chemotherapeutic agents to improve clinical outcomes or alleviate side effects for patients with advanced HCC.
7.
Her-Shyong Shiah Nai-Jung Chiang Chia-Chi Lin Chia-Jui Yen Hui-Jen Tsai Shang-Yin Wu Wu-Chou Su Kwang-Yu Chang Ching-Chiung Wang Jang-Yang Chang Li-Tzong Chen 《The oncologist》2021,26(4):e567-e579
Lessons Learned
- SCB01A is a novel microtubule inhibitor with vascular disrupting activity.
- This first‐in‐human study demonstrated SCB01A safety, pharmacokinetics, and preliminary antitumor activity.
- SCB01A is safe and well tolerated in patients with advanced solid malignancies with manageable neurotoxicity.
8.
9.
Brandon Ginley Kuang-Yu Jen Seung Seok Han Luís Rodrigues Sanjay Jain Agnes B. Fogo Jonathan Zuckerman Vighnesh Walavalkar Jeffrey C. Miecznikowski Yumeng Wen Felicia Yen Donghwan Yun Kyung Chul Moon Avi Rosenberg Chirag Parikh Pinaki Sarder 《Journal of the American Society of Nephrology : JASN》2021,32(4):837
10.
Andrew X. Zhu Richard S. Finn Yoon-Koo Kang Chia-Jui Yen Peter R. Galle Josep M. Llovet Eric Assenat Giovanni Brandi Kenta Motomura Izumi Ohno Bruno Daniele Arndt Vogel Tatsuya Yamashita Chih-Hung Hsu Guido Gerken John Bilbruck Yanzhi Hsu Kun Liang Ryan C. Widau Chunxiao Wang Paolo Abada Masatoshi Kudo 《British journal of cancer》2021,124(8):1388
Background Post hoc analyses assessed the prognostic and predictive value of baseline alpha-fetoprotein (AFP), as well as clinical outcomes by AFP response or progression, during treatment in two placebo-controlled trials (REACH, REACH-2).Methods Serum AFP was measured at baseline and every three cycles. The prognostic and predictive value of baseline AFP was assessed by Cox regression models and Subpopulation Treatment Effect Pattern Plot method. Associations between AFP (≥ 20% increase) and radiographic progression and efficacy were assessed.Results Baseline AFP was confirmed as a continuous (REACH, REACH-2; p < 0.0001) and dichotomous (≥400 vs. <400 ng/ml; REACH, p < 0.01) prognostic factor, and was predictive for ramucirumab survival benefit in REACH (p = 0.0042 continuous; p < 0.0001 dichotomous). Time to AFP (hazard ratio [HR] 0.513; p < 0.0001) and radiographic (HR 0.549; p < 0.0001) progression favoured ramucirumab. Association between AFP and radiographic progression was shown for up to 6 (odds ratio [OR] 5.1; p < 0.0001) and 6–12 weeks (OR 1.8; p = 0.0065). AFP response was higher with ramucirumab vs. placebo (p < 0.0001). Survival was longer in patients with an AFP response than patients without (13.6 vs. 5.6 months, HR 0.451; 95% confidence interval, 0.354–0.574; p < 0.0001).Conclusions AFP is an important prognostic factor and a predictive biomarker for ramucirumab survival benefit. AFP ≥ 400 ng/ml is an appropriate selection criterion for ramucirumab.Clinical Trial Registration ClinicalTrials.gov, REACH () and REACH-2 ( NCT01140347).Subject terms: NCT02435433Oncology, Biomarkers 相似文献